Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.37 |
| ▸ | RXRB | P28702 | 4/20 | 0.35 |
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753406 | 0.95 | CETP (0.38) | CETP | |
| SCHEMBL5752919 | 0.95 | PTGER4 (0.38) | PTGER4CETPPTGER2 | |
| SCHEMBL5751849 | 0.94 | MAPT (0.37) | PTGER4NPC1RAB9AMRGPRX4SMN1; SMN2 | |
| SCHEMBL5754604 | 0.93 | CETP (0.35) | CETPMEN1KMT2A | |
| SCHEMBL5753597 | 0.90 | CETP (0.40) | SMN1; SMN2CETPMEN1KMT2A | |
| SCHEMBL5751913 | 0.90 | CETP (0.34) | PTGER4CETP | |
| SCHEMBL5749922 | 0.90 | CETP (0.34) | PTGER4CETP | |
| SCHEMBL1899668 | 0.89 | CETP (0.38) | CETP | |
| SCHEMBL5752659 | 0.89 | CETP (0.35) | CETPMAPT | |
| SCHEMBL5749781 | 0.88 | CETP (0.33) | PTGER4CETPPTGER2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PTGER4 1632/4885RXRB 2124/4885RXRA 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.